These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2856188)

  • 21. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo.
    Darius H; Smith JB; Lefer AM
    J Pharmacol Exp Ther; 1985 Nov; 235(2):274-81. PubMed ID: 2997428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ethanol on pathways of platelet aggregation in vitro.
    Rand ML; Packham MA; Kinlough-Rathbone RL; Fraser Mustard J
    Thromb Haemost; 1988 Jun; 59(3):383-7. PubMed ID: 3142075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
    Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
    Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b,f)thiepin 5,5-dioxide (L-640,035).
    Chan CC; Nathaniel DJ; Yusko PJ; Hall RA; Ford-Hutchinson AW
    J Pharmacol Exp Ther; 1984 Apr; 229(1):276-82. PubMed ID: 6423813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The modification of the biosynthesis and effect of thromboxane A2 and prostacyclin by trapidil (Rocornal)].
    Block HU; Heinroth I; Giessler C; Pönicke K; Mentz P; Zehl U; Rettkowski W; Dunemann A; Förster W
    Biomed Biochim Acta; 1983; 42(2-3):283-99. PubMed ID: 6411078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.
    Schumacher WA; Lucchesi BR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
    Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
    Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
    Ashton JH; Schmitz JM; Campbell WB; Ogletree ML; Raheja S; Taylor AL; Fitzgerald C; Buja LM; Willerson JT
    Circ Res; 1986 Nov; 59(5):568-78. PubMed ID: 3542279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation.
    Golino P; Ambrosio G; Pascucci I; Ragni M; Russolillo E; Chiariello M
    Thromb Haemost; 1992 Mar; 67(3):302-5. PubMed ID: 1641819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood.
    Heptinstall S; May JA; Glenn JR; Sanderson HM; Dickinson JP; Wilcox RG
    Thromb Haemost; 1995 Nov; 74(5):1310-5. PubMed ID: 8607115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
    Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
    J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
    Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
    Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia.
    Grover GJ; Schumacher WA
    Basic Res Cardiol; 1989; 84(1):103-10. PubMed ID: 2522297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
    Darius H; Lefer AM
    Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ; Leis LA; Francis GS
    Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
    Thomas M; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
    Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.